[As adopted in Release No. 34-32231, April 28, 1993, 58 F.R. 26509]

                     U.S. Securities and Exchange Commission

                             Washington, D.C. 20549

                                   Form 10-QSB

(Mark One)
       [X]   QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

             For the quarterly period ended:      October 31, 2000
                                            -----------------------------

       [ ]   TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE
                                  EXCHANGE ACT

         For the transition period from                 to
                                         --------------   ----------------
                 Commission file number           0-730
                                         -----------------------

                               My Meds Express.Com
                  ---------------------------------------------
                     (Exact name of small business issuer as
                            specified in its charter)

    Delaware                                                      84-1398190
--------------------------------------------------------------------------------
(State or other jurisdiction                                   (IRS Employer
of incorporation or organization)                            Identification No.)

                        BOX 8029, La Jolla, CA 92037-8029
                    (Address of principal executive offices)

                                 (619) 456-7176
                            Issuer's telephone number


              (Former name, former address and former fiscal year,
                         if changed since last report.)

     Check  whether  the issuer (1) filed all  reports  required  to be filed by
Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or for such
shorter period that the  registrant was required to file such reports),  and (2)
has been subject to such filing requirements for the past 90 days. Yes No X



<PAGE>



                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDING DURING THE PRECEDING FIVE YEARS

     Check whether the registrant filed all documents and reports required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the  distribution  of
securities under a plan confirmed by a court. Yes No X


                      APPLICABLE ONLY TO CORPORATE ISSUERS

     State the number of shares  outstanding of each of the issuer's  classes of
common  equity,  as of the latest  practical  date:  December 15, 2000 2,177,647
                                                     ---------------------------

     Transitional Small Business  Disclosure Format (check one). Yes ; No X



<PAGE>



                         PART I - FINANCIAL INFORMATION

Item 1.  Financial Statements




                          INDEPENDENT AUDITOR'S REPORT


MY MEDS EXPRESS.COM, INC.
(A Development Stage Company)


     We have reviewed the  accompanying  balance sheets of My Meds  Express.Com,
Inc.(a  development stage company) as of October 31, 2000 and July 31, 2000, and
the related  statements of operations  and cash flows for the three months ended
October 31, 2000 and 1999. These financial  statements are the responsibility of
the Company's management.

     We conducted our review in accordance with standards established by
the  American  Institute of Certified  Public  Accountants.  A review of interim
financial  information consists principally of applying analytical procedures to
financial  data and making  inquiries of persons  responsible  for financial and
accounting matters. It is substantially less in scope than an audit conducted in
accordance with generally accepted auditing standards, the objective of which is
the expression of an opinion regarding the financial statement taken as a whole.
Accordingly, we do not express such an opinion.

     Based on our review,  we are not aware of any material  modifications  that
should  be made  to the  accompanying  financial  statements  for  them to be in
conformity with generally accepted accounting principles.

                                              Respectfully submitted



                                              /s/ ROBISON, HILL & CO.
                                              Certified Public Accountants

Salt Lake City, Utah
December 15, 2000





                                        3

<PAGE>



                               MY MEDS EXPRESS.COM
                          (A Development Stage Company)
                                 BALANCE SHEETS
                                   (Unaudited)



                                                      October 31,     July 31,
                                                      -----------   -----------
                                                         2000          2000
                                                      -----------   -----------
ASSETS .............................................  $      --     $      --
                                                      ===========   ===========


LIABILITIES AND STOCKHOLDERS' EQUITY
Liabilities:
  Accounts Payable .................................  $        60   $        60
  Shareholder Advances .............................        8,045         8,045
                                                      -----------   -----------

          Total Liabilities ........................        8,105         8,105
                                                      -----------   -----------

Stockholders' Equity
Preferred  stock (par value $.001)..................
  5,000,000 shares authorized,
  630 shares issued at October 31, 2000 and
 July 31, 2000 .....................................            1             1
Common stock (par value $.001), 50,000,000 shares
  authorized, 2,177,647 shares issued and
  outstanding October 31, 2000 and July 31, 2000 ...        2,178         2,178
Capital in excess of par value .....................    2,934,636     2,934,636
Retained deficit ...................................   (2,933,986)   (2,933,986)
Deficit accumulated during development stage .......      (10,934)      (10,934)
                                                      -----------   -----------

          Total Stockholders' Equity ...............       (8,105)       (8,105)
                                                      -----------   -----------

          Total Liabilities and Stockholders' Equity  $      --     $      --
                                                      ===========   ===========











                 See accompanying notes and accountants' report


                                        4

<PAGE>



                               MY MEDS EXPRESS.COM
                          (A Development Stage Company)
                             STATEMENT OF OPERATIONS
                                   (Unaudited)




                                                               Cumulative
                                                                  Since
                                                               April 2, 1996
                                  For the Three Months Ended   Inception of
                                         October 31,           Development
                                 -----------------------------
                                     2000            1999        Stage
                                 --------------  -------------  --------
Revenues ......................  $         --    $        --    $   --


Expenses ......................            --             --      10,934
                                 --------------  -------------  --------

       Net Loss ...............  $         --    $        --    $(10,934)
                                 ==============  =============  ========


Basic & Diluted  loss per share  $         --    $        --
                                 ==============  =============

























                 See accompanying notes and accountants' report

                                        5

<PAGE>



                               MY MEDS EXPRESS.COM
                          (A Development Stage Company)
                             STATEMENT OF CASH FLOWS
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                         Cumulative
                                                                           Since
                                                                         April 2, 1996
                                                                         Inception
                                             For the three months ended     of
                                                   October 31,           Development
                                             --------------------------
                                                 2000           1999     Stage
                                             -------------  -----------  --------
CASH FLOWS FROM OPERATING
ACTIVITIES:
<S>                                          <C>            <C>          <C>
Net Loss ..................................  $        --    $      --    $(10,934)
Increase (Decrease) in Accounts Payable ...           --           --      (1,406)
                                             -------------  -----------  --------
  Net Cash Used in operating activities ...           --           --     (12,340)
                                             -------------  -----------  --------

CASH FLOWS FROM INVESTING
ACTIVITIES:
  Net cash provided by investing activities           --           --        --
                                             -------------  -----------  --------

CASH FLOWS FROM FINANCING
ACTIVITIES:
Proceeds From Shareholder Advances ........           --           --       8,045
Proceeds From Capital Stock Issued ........           --           --       4,295
                                             -------------  -----------  --------
  Net cash provided by financing activities           --           --      12,340
                                             -------------  -----------  --------

Net (Decrease) Increase in
  Cash and Cash Equivalents ...............           --           --        --
Cash and Cash Equivalents
  at Beginning of Period ..................           --           --        --
                                             -------------  -----------  --------
Cash and Cash Equivalents
  at End of Period ........................  $        --    $      --    $   --
                                             =============  ===========  ========

SUPPLEMENTAL DISCLOSURE
OF CASH FLOW INFORMATION:

Cash paid during the year for:
  Interest ................................  $        --    $      --    $   --
  Franchise and income taxes ..............           --             --       1,586

SUPPLEMENTAL DISCLOSURE OF NON-
CASH INVESTING AND FINANCING
ACTIVITIES:
  None
</TABLE>
                 See accompanying notes and accountants' report

                                        6

<PAGE>



                               MY MEDS EXPRESS.COM
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                   FOR THE THREE MONTHS ENDED OCTOBER 31, 2000
                                   (Unaudited)

NOTE 1 - ORGANIZATION AND SUMMARY OF ACCOUNTING POLICIES

     The  accompanying  unaudited  financial  statements  have been  prepared in
accordance with generally  accepted  accounting  principles and with Form 10-QSB
requirements.  Accordingly,  they  do not  include  all of the  information  and
footnotes  required by generally  accepted  accounting  principles  for complete
financial statements.  In the opinion of management,  all adjustments considered
necessary for a fair presentation have been included.  Operating results for the
three month period ended October 31, 2000, are not necessarily indicative of the
results that may be expected for the year ended July 31, 2001.

Organization and Basis of Presentation

     Plaza  Group,   Inc.,   hereinafter   referred  to  as  the  "Company"  was
incorporated  on April 24, 1984 under the laws of the State of Delaware  for the
principal purpose of engaging in any and all types of business properties.

General:

     On November 7, 1984 the United States  Securities  and Exchange  Commission
granted  an  effective  date to a  registration  statement  on S-18 filed by the
Company  in  the  Denver  office,  as  Commission  File  Number  2-91824-D.  The
registration statement was for offering of 800,000 Units at $0.50 per unit.

     The offering file by the Company was a "Blank  Check"offering and since the
date of incorporation the company has not engaged in any meaningful business and
is  considered a development  stage  company.  The company  ceased all operating
activities  during  the  period  from July 31,  1987 to March  24,  1996 and was
considered dormant.

     The proposed business activities  described herein may classify the Company
as a "Blank  Check"  company.  Many  states  have  entered  statutes,  rules and
regulations  limiting the sale of securities of "Blank Check" companies in their
respective  jurisdictions.  In order to comply with these  various  limitations,
management  does not intend to  undertake  any  efforts  to sell any  additional
securities of the Company,  either debt or equity,  or cause a market to develop
in the  Company's  securities  until such time as the Company  has  successfully
implemented its business plan described herein.

     On April 2, 1996, the Company obtained a certificate of renewal from
the State of Delaware.  On April 2, 1996 the Company  obtained a certificate  of
amendment of "Plaza Group, Inc., changing


                                        7

<PAGE>



                               MY MEDS EXPRESS.COM
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                   FOR THE THREE MONTHS ENDED OCTOBER 31, 2000
                                   (Unaudited)


General: (Continued)

the name from Plaza  Group,  Inc to Union 69,  Ltd. On March 2, 2000 the Company
changed its name to Save on Meds.Com, Inc.

Nature of Business:
------------------

     The Company's  purpose is to seek,  investigate and, if such  investigation
warrants,  acquire an  interest  in business  opportunities  presented  to it by
persons  or firms who or which  desire  to seek the  perceived  advantages  of a
Corporation which reports under Section 13 and 15 of the Securities Exchange Act
of 1934 ( the "Exchange  Act").  The Company will not restrict its search to any
specific  business;  industry  or  geographical  location  and the  Company  may
participate in a business  venture of virtually  unlimited  discretion to search
for and enter into potential business opportunities. Management anticipates that
it may be able to participate on only one potential business venture because the
Company  has  nominal  assets  and  limited  financial  resources.  This lack of
diversification  should be considered a substantial  risk ro shareholders of the
Company because it will not permit the Company to offset  potential  losses from
one venture against gains from another.

Cash and Cash Equivalents:
-------------------------

     For purposes of the  statement  of cash flows,  the Company  considers  all
highly liquid debt instruments purchased with a maturity of three months or less
to be cash equivalents to the extent the funds are not being held for investment
purposes.

Pervasiveness of Estimates

     The  preparation  of financial  statements  in  conformity  with  generally
accepted  accounting  principles  required  management  to  make  estimates  and
assumptions  that  affect the  reported  amounts of assets and  liabilities  and
disclosure of  contingent  assets and  liabilities  at the date of the financial
statements  and the  reported  amounts  of  revenues  and  expenses  during  the
reporting period. Actual results could differ from those estimates.








                                        8

<PAGE>



                               MY MEDS EXPRESS.COM
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                   FOR THE THREE MONTHS ENDED OCTOBER 31, 2000
                                   (Unaudited)

NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(Continued)

Loss Per Share:

     The  reconciliations  of the numerators and  denominators of the basic loss
per share computations are as follows:


                                                               Per-Share
                                  Income        Shares           Amount
                                  ------        ------           ------
                                (Numerator)   (Denominator)

                                  For the three months ended October 31, 2000
Basic Income per Share
Income to common shareholders  $          -        2,177,647   $          -
                               ============  ===============   ============

                                  For the three months ended October 31, 1999
Basic Loss per Share
Loss to common shareholders    $          -        1,377,647   $          -
                               ============  ===============   ============

     The effect of outstanding  common stock  equivalents would be anti-dilutive
or immaterial for 2000 and are thus not considered.

Concentration of Credit Risk

     The Company has no significant  off-balance-sheet  concentrations of credit
risk such as foreign  exchange  contracts,  options  contracts or other  foreign
hedging arrangements.

NOTE 2 - CONVERTIBLE PREFERRED STOCK

     The  convertible  preferred  stock is convertible  into common stock at the
option  of the  shareholder  at  any  time  after  issuance  of the  convertible
preferred  shares.  The conversion  ratio is one share of convertible  preferred
stock for 30,000 shares of common stock.  The holders of  convertible  preferred
stock  shall be  entitled  to vote on all  matters  at the ratio of one vote per
share of common  stock  that it is  convertible  into as if the  shares had been
converted.  In the event of any voluntary or involuntary  liquidations  (whether
complete or partial), dissolution, or winding up of the corporation, the holders
of the  convertible  preferred  stock  shall be entitled to be paid an amount in
cash equal to the net book value of the  corporation on the date of liquidation,
plus all unpaid dividends,  whether or not previously declared,  accrued thereon
to the date of final distribution.

                                        9

<PAGE>



                               MY MEDS EXPRESS.COM
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                   FOR THE THREE MONTHS ENDED OCTOBER 31, 2000
                                   (Unaudited)

NOTE 3 - INCOME TAXES

     As of October 31, 2000, the Company had a net operating  loss  carryforward
for income tax reporting purposes of approximately $2,900,000 that may be offset
against future taxable income through 2011. Current tax laws limit the amount of
loss  available to be offset  against  future  taxable income when a substantial
change in ownership  occurs.  Therefore,  the amount  available to offset future
taxable income may be limited. No tax benefit has been reported in the financial
statements,  because the Company  believes  there is a 50% or greater chance the
carry-forward will expire unused. Accordingly, the potential tax benefits of the
loss carry-forward are offset by a valuation allowance of the same amount.

NOTE 4 - DEVELOPMENT STAGE COMPANY

     The  Company  has not begun  principal  operations  and as is common with a
development  stage  company,  the Company has had  recurring  losses  during its
development stage.

NOTE 5 - COMMITMENTS

     As of October 31, 2000 all activities of the Company have been conducted by
corporate officers from either their homes or business offices. Currently, there
are no outstanding debts owed by the company for the use of these facilities and
there are no commitments for future use of the facilities.


















                                       10

<PAGE>



Item 2.  Management's Discussion and Analysis or Plan of Operation.

General  - This  discussion  should  be read in  conjunction  with  Management's
Discussion and Analysis of Financial  Condition and Results of Operations in the
Company's annual report on Form 10-KSB for the year ended July 31, 2000.

Item 2.  Management's Discussion and Analysis or Plan of Operation (Continued)

Results of  Operations  -For the quarter  ended  October 31, 2000 compare to the
same period in 1999 are not  necessarily  indicative  of the results that may be
expected for the year ended July 31, 2001.

The Company has no  business  operations.  The Company had $0 and $0 in expenses
for the three month period ended  October 31, 2000 and 1999.  The Company had no
revenues for the three month period ended  October 31, 2000 and 1999.  Losses on
operations may occur until sufficient revenues can be achieved.

Liquidity and Capital Resources

     The  Company  requires  working  capital  principally  to fund its  current
operations.  There are no formal commitments from banks or other lending sources
for lines of credit or similar  short-term  borrowing,  but the Company has been
able to borrow any additional working capital that has been required.  From time
to time in the past,  required  short-term  borrowing  have been obtained from a
principal shareholder or other related entities.

     In order to  complete  any  acquisition,  the  Company  may be  required to
supplement  its  available  cash and other  liquid  assets  with  proceeds  from
borrowings,  the sale of additional securities,  including the private placement
of restricted stock and/or a public offering, or other sources.  There can be no
assurance  that  any such  required  additional  funding  will be  available  or
favorable to the Company.

     Because  management  controls  93.47%  of  voting  rights,  management  may
actively  negotiate or otherwise consent to the purchase of any portion of their
stock as a condition to or in connection  with a proposed merger or acquisition.
Furthermore,  management  could consent or approve any particular  stock buy-out
transaction  without  shareholder  approval.  In the event  that an  appropriate
merger  candidate is located,  the Company may need to pay cash finder's fees or
other  acquisition  related  compensation  may be paid to  officers,  directors,
promoters  or their  affiliates.  Any such  finder's  fees  paid to an  officer,
director,  promoter,  or affiliate may present a conflict of interest because of
the non-arms length nature of such  transaction.  There are no such negotiations
in progress or contemplated.

     There  are  no  arrangements  or  understandings   between   non-management
shareholders and management under which non-management shareholders may directly
or  indirectly  participate  in or influence  the  management  of the  Company's
affairs.



                                       11

<PAGE>



                           PART II - OTHER INFORMATION


Item 1.  Legal Proceedings

       None.

Item 2.  Changes in Securities

       None.

Item 3.  Defaults Upon Senior Securities

       None.

Item 4.  Submission of Matters to a Vote of Security Holders.

       None.

Item 5.  Other Information

       None.

Item 6.  Exhibits and Reports on Form 8-K

     The Company did not file a report on Form 8-K during the three months ended
October 31, 2000.


                                       12

<PAGE>


                                   SIGNATURES



     In accordance  with the  requirements  of the Exchange Act, the  registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.



                               MY MEDS EXPRESS.COM
                               -------------------
                                  (Registrant)





DATE:   December 20, 2000                   By:  /s/
     --------------------------                  ----
                                                 Michael Johnson, President
                                                 (Principal Financial and
                                                 Accounting Officer)


                                       13